The difficult balance between thrombosis and bleeding after transcatheter aortic valve replacement: A translational review.


Journal

Archives of cardiovascular diseases
ISSN: 1875-2128
Titre abrégé: Arch Cardiovasc Dis
Pays: Netherlands
ID NLM: 101465655

Informations de publication

Date de publication:
Apr 2020
Historique:
received: 26 07 2019
revised: 26 11 2019
accepted: 02 12 2019
pubmed: 15 2 2020
medline: 7 7 2020
entrez: 15 2 2020
Statut: ppublish

Résumé

Transcatheter aortic valve replacement (TAVR) has emerged as the treatment of choice for patients with severe aortic stenosis deemed at high or intermediate risk for cardiac surgery. In light of the latest literature advances, TAVR will undoubtedly concern a growing number of patients because of the progressive extension of its indications. Whereas significant efforts have been made to reduce the burden of periprocedural complications, TAVR still exposes patients to a sizeable number of adverse outcomes, including thrombotic and bleeding events. Although contradictory, these two phenomena are closely related to pathophysiological processes inherent to flow disturbances induced by aortic stenosis itself, but also to a complex interaction between bioprosthetic valves and native tissues in frail patients clustering various co-morbidities. Reinforcing this paradigm, multiple TAVR studies have emphasized the view that both thrombosis and bleeding events have a deleterious effect on patient outcomes. Therefore, we sought to perform a comprehensive translational review of the current literature addressing the pathophysiological mechanisms leading to thrombosis and bleeding after TAVR, and underline innovative strategies aimed at reducing these complications.

Identifiants

pubmed: 32057662
pii: S1875-2136(20)30019-X
doi: 10.1016/j.acvd.2019.12.003
pii:
doi:

Substances chimiques

Anticoagulants 0
Fibrinolytic Agents 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

263-275

Informations de copyright

Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Auteurs

Antonin Trimaille (A)

Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Université de Strasbourg, BP 426, 67091 Strasbourg, France. Electronic address: antonin.trimaille@chru-strasbourg.fr.

Benjamin Marchandot (B)

Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Université de Strasbourg, BP 426, 67091 Strasbourg, France.

Sin-Hee Park (SH)

Regenerative NanoMedicine, UMR 1260, Inserm, Université de Strasbourg, 67085 Strasbourg, France.

Valérie Schini-Kerth (V)

Regenerative NanoMedicine, UMR 1260, Inserm, Université de Strasbourg, 67085 Strasbourg, France.

Olivier Morel (O)

Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Université de Strasbourg, BP 426, 67091 Strasbourg, France; Regenerative NanoMedicine, UMR 1260, Inserm, Université de Strasbourg, 67085 Strasbourg, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH